Overview

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
Phase:
Phase 2
Details
Lead Sponsor:
MedSIR
Collaborator:
Daiichi Sankyo, Inc.
Treatments:
Trastuzumab